Filter

411-420 of 537 results

  • Medicare Advantage 2021 Spotlight: First Look

    Issue Brief

    For 2021, the average Medicare beneficiary has access to 33 Medicare Advantage plans, the largest number of options available in the last decade, and can choose from plans offered by eight firms. Among the majority of Medicare Advantage plans that cover prescription drugs, 54 percent will charge no premium in addition to the monthly Medicare Part B premium. As in previous years, the vast majority of Medicare Advantage plans will offer supplemental fitness, dental, vision,…

  • Health Affairs Blog: Medicare Premium Support Proposals Could Increase Costs for Today’s Seniors, Despite Assurances

    Perspective

    In a Health Affairs blog post, Tricia Neuman and Gretchen Jacobson of the Kaiser Family Foundation examine how proposals to convert Medicare to a premium support system could lead to higher Medicare premiums and cost-sharing for seniors currently enrolled in the program, even if today’s seniors are “grandfathered” and the new system is phased-in for people ages 55 and younger. The blog post explains how today’s seniors could face higher health care costs, if older…

  • Views and Experiences with End-of-Life Medical Care in the U.S.

    Report

    In partnership with The Economist, the Kaiser Family Foundation conducted a cross-country survey of adults in the United States, Japan, Italy, and Brazil about people’s views and experiences related to aging and end-of-life medical care. This report gives an overview of the U.S. survey results, including ratings of the health care system, personal preferences, conversations and planning related to end-of-life wishes, and experiences with loved ones’ death.

  • Views and Experiences with End-of-Life Medical Care in Japan, Italy, the United States, and Brazil: A Cross-Country Survey

    Report

    In partnership with The Economist, the Kaiser Family Foundation conducted a cross-country survey of adults in Japan, Italy, the United States, and Brazil about people’s views and experiences related to aging and end-of-life medical care. This report summarizes the overall survey results with comparisons across the four countries. Topics covered in the survey include ratings of the health care system, personal preferences, conversations and planning related to end-of-life wishes, and experiences with loved ones’ death.

  • Kaiser/Economist Survey Highlights Americans’ Views and Experiences with End-of-Life Care, With Comparisons to Residents of Italy, Japan and Brazil

    News Release

    Half of Americans -- including nearly six in ten of those in fair or poor health – say people in the U.S. have too little control over their end-of-life medical decisions, finds a new Kaiser Family Foundation/Economist survey examining views and experiences with end-of-life care in the U.S. and three other nations. The cross-country survey and related journalism in The Economist’s April 29 issue highlight Americans’ experiences and opinions about aging and end-of-life care and…

  • State Variation in Medicaid Per Enrollee Spending for Seniors and People with Disabilities

    Issue Brief

    This issue brief explains the variation in Medicaid spending per enrollee for seniors, nonelderly adults with disabilities, and children with disabilities compared to other populations as well as the variation in per enrollee spending for these populations among states. It also provides a snapshot of state choices about optional eligibility pathways and services important to many seniors and people with disabilities.

  • Summary of Costs and Impact of the Prescription Drug Provisions in the Build Back Better Act

    News Release

    As the House-passed Build Back Better Act moves to the Senate, a new explainer from KFF summarizes the key prescription drug provisions within the broader budget reconciliation bill. These provisions would lower prescription drug costs paid by people with Medicare and private insurance and curb drug spending by the federal government and private payers. The Congressional Budget Office estimates federal budget savings from the drug pricing provisions would be $297 billion over 10 years. Although…